Characterization of HER2-Positive Murine Breast Cancer Models for Investigating HER2-Targeted Therapy and Immunotherapy
Open Access
Abstract
Background/Objectives: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is linked to poorer overall survival and a higher risk of brain metastases compared to HER2-negative breast cancer. Current preclinical studies lack robust HER2+ metastatic syngeneic mouse models for investigating targeted and immunomodulatory therapies. This study aims to develop effective HER2+ mouse models to investigate response dynamics to HER2-targeted therapy and immunotherapy. Methods: The human HER2 gene (WT or mutant p.A775_G776insYVMA, GFP-tagged at the C-terminus) was introduced into triple-negative breast cancer (TNBC) mouse mammary carcinoma cells with known metastatic potential (4T1 and EO771) via lentiviral transduction. HER2 expression and phosphorylation were analyzed using Western blotting and immunohistochemistry. Tumors were treated with HER2-targeted therapy (trastuzumab and tucatinib), immune checkpoint blockade (anti-PD-1 and anti-CTLA-4), and anti-HER2 antibody–drug conjugate (ADC) to evaluate treatment efficacy. Metastatic potential was assessed with brain fluorescence imaging. Statistical analysis included ANOVA and Kaplan–Meier tests. Results: Newly established lines demonstrated expression of HER2+, with HER2YVMA lines showing higher phosphorylation than HER2WT lines. Cells were tumorigenic, demonstrating in vivo tumor take rates at 100% for 4T1-HER2 and 15–30% for EO771-HER2. HER2 overexpression led to a 30% increase in spontaneous brain metastasis in the 4T1-HER2 models. Trastuzumab alone did not reduce primary tumor size but significantly reduced brain GFP signal by 17% ± 8% and 26% ± 7% in the 4T1-HER2WT and 4T1-HER2YVMA models, respectively. Combinational therapies with anti-HER2 therapy and immune checkpoint blockade effectively suppressed primary tumor growth and prolonged survival in EO771-HER2YVMA model. T-Dxd, but not T-DM1, demonstrated partial treatment response in the EO771-HER2WT model. Conclusions: HER2+ syngeneic tumor models were developed that spontaneously metastasize to the brain and demonstrate variable responses to immunotherapies and ADCs. These models are valuable for advancing molecular imaging modalities for HER2+ brain metastasis, studying blood–brain barrier penetration of HER2-targeted drugs, and exploring the combination of therapies, including immunotherapy.Keywords
Funding Information
- National Cancer Institute (R01CA240589)
- National Cancer Institute (R01CA276540)
- National Institute of General Medical Sciences (T32GM156741)
- NIH (P30CA013148)
This publication has 46 references indexed in Scilit:
- Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsiesnpj Breast Cancer, 2025
- Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trialESMO Open, 2024
- Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study GroupESMO Open, 2022
- HER2-low breast cancer could be associated with an increased risk of brain metastasisInternational Journal of Clinical Oncology, 2021
- How we treat HER2-positive brain metastasesESMO Open, 2021
- Immunotherapy and targeted therapy combinations in metastatic breast cancerThe Lancet Oncology, 2019
- Characterization of passive permeability at the blood–tumor barrier in five preclinical models of brain metastases of breast cancerClinical & Experimental Metastasis, 2016
- Understanding Heterogeneity and Permeability of Brain Metastases in Murine Models of HER2-Positive Breast Cancer Through Magnetic Resonance Imaging: Implications for Detection and TherapyTranslational Oncology, 2015
- Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediatorsOncogene, 2010
- HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitorsCancer Cell, 2006